Zentalis Pharmaceuticals, Inc.
ZNTL
$3.87
-$0.16-3.97%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 26.87M | 26.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 26.87M | 26.87M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | 26.87M | 26.87M |
| SG&A Expenses | 32.92M | 32.14M | 33.58M | 69.82M | 73.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 150.44M | 142.10M | 140.88M | 179.40M | 197.10M |
| Operating Income | -150.44M | -142.10M | -140.88M | -152.53M | -170.23M |
| Income Before Tax | -138.85M | -123.57M | -136.62M | -149.52M | -163.02M |
| Income Tax Expenses | 700.00K | 562.00K | 442.00K | -205.00K | -232.00K |
| Earnings from Continuing Operations | -139.55 | -124.13 | -137.06 | -149.32 | -162.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | 0.00 | 0.00 |
| Net Income | -139.55M | -124.13M | -137.06M | -149.32M | -162.78M |
| EBIT | -150.44M | -142.10M | -140.88M | -152.53M | -170.23M |
| EBITDA | -149.82M | -141.48M | -140.14M | -151.63M | -169.17M |
| EPS Basic | -1.96 | -1.74 | -1.91 | -2.08 | -2.28 |
| Normalized Basic EPS | -1.21 | -1.08 | -1.05 | -1.18 | -1.30 |
| EPS Diluted | -1.96 | -1.74 | -1.91 | -2.08 | -2.28 |
| Normalized Diluted EPS | -1.21 | -1.08 | -1.05 | -1.18 | -1.30 |
| Average Basic Shares Outstanding | 285.39M | 286.06M | 287.47M | 287.08M | 286.05M |
| Average Diluted Shares Outstanding | 285.39M | 286.06M | 287.47M | 287.08M | 286.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |